News : positive results

View:
 

Found press releases

 

Positive study results for OX27

12/20/2011 7:00 AM EST  -   Orexo
Uppsala - December 20, 2011 - Orexo AB (STO: ORX) has obtained positive results in a pharmacokinetic study with the OX27 project. The study was conducted on healthy subjects, with the aim to demonstrate that OX27 has the potential for more flexible dosing than fentanyl based products.

OX27 is a sublingual (under the tongue) tablet, developed to improve the treatment of breakthrough pain in cancer patients. The...

MOBERG DERMA REPORTS POSITIVE CLINICAL RESULTS FOR EMTRIX

2/2/2011 4:45 AM EST  -   MOBERG DERMA AB
Moberg Derma AB today reports positive results from a clinical trial of Emtrix. The trial included 75 patients with nail fungus (onychomycosis) and the results showed that 92% of the patients improved after 8 weeks of treatment. Already after 2 weeks, 77% of the patients were improved.
The open clinical trial was conducted at two clinical centers in Sweden during the second half of 2010. The purpose was to...

MOBERG DERMA REPORTS POSITIVE PHASE II RESULTS FOR K201 AGAINST ATOPIC ECZEMA

11/20/2009 8:05 AM EST  -   MOBERG DERMA AB
Moberg Derma AB reports today positive results from a phase II clinical study for K201 against atopic eczema. The study which included 30 patients with mild to moderate eczema showed that treatment with K201 resulted in statistically significant improvement of clinical skin condition, skin barrier and skin hydration. The study results also indicated that K201 can prevent growth of commonly occurring bacteria in...

MOBERG DERMA SECURED SEK 35 MILLION IN NEW SHARE ISSUE

8/24/2009 2:00 AM EST  -   MOBERG DERMA AB
The pharmaceutical company Moberg Derma recently secured SEK 35 million in a new share issue. Both existing and new shareholders subscribed for shares in the issue. More than SEK 100 million has now been raised for its operations since the company was established in March 2006.
“We are very pleased with the interest shown by investors what has been a difficult market climate in recently. The new share issue has...
Peter Wolpert, CEO Moberg Derma
 

MOBERG DERMA REPORTS POSITIVE PHASE III RESULTS FOR K101 AGAINST NAIL FUNGUS

11/20/2008 8:50 AM EST  -   MOBERG DERMA AB
Moberg Derma AB reports today positive results from a phase III clinical study for K101 against nail fungus (onychomycosis). In the study, almost 500 patients were treated during six months with K101 or a placebo. The results showed that significantly more patients receiving K101 were cured of their fungal infection (p=0.001). The patients' subjective evaluation of the treatment effect revealed distinct benefits...